Technology and Professional Services Contract Will Support Innovation in Combat Casualty Care
May 25, 2022
Towson, Md., May 25, 2022 – PM Consulting Group (PMCG) today announced the company has been selected by the Defense Health Agency (DHA) as a contract recipient under its Omnibus IV Medical Research and Development initiative. This is an indefinite delivery/indefinite quantity (IDIQ), multiple-award contract, with a potential total value of $10 billion.
PMCG is one of 56 awardees now qualified to perform technology and professional services in support of DHA’s programs, which seek to transition findings and innovations from the research and development (R&D) phase into medical practice to improve combat casualty care.
“No mission is more important to us than the health of our nation’s servicemembers,” said
Walter Barnes III, President of PM Consulting Group. “We’re proud to apply our expertise and support services on behalf of DHA efforts to improve force health readiness and rehabilitation.”
PMCG’s existing work with DHA, the U.S. Army Reserve, and the U.S. Agency for
International Development (USAID) positioned the company well for the new IDIQ.
“Our team will help DHA foster sound, sustained advances in medical science through our
commitment to excellence across the R&D process,” said Spencer Hedden, Vice President of
Strategic Growth for PM Consulting Group.
“It’s an honor to be able to serve the men and women who protect this country, and we
understand and accept the responsibility that comes with it. We look forward to helping DHA find and create real-world, tangible solutions for the military’s healthcare needs.”
Vistant is a Maryland-based consultancy that specializes in International Development, Advanced Healthcare, and Federal Government solutions. Visit Vistant at vistantco.com.
Vistant (PM Consulting Group) contracting vehicles: OASIS SB/8a Pool 1 (47QRAD20D1060/47QRAD20D8121); GSA 8a STARS III (47QTCB22D0222); and GSA MAS (GS-00F-166GA)